Trial Profile
A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-Controlled Trial of Ethyl-EPA in Subjects With Mild to Moderate Huntington's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Apr 2009
Price :
$35
*
At a glance
- Drugs Ethyl eicosapentaenoic acid (Primary)
- Indications Huntington's disease
- Focus Therapeutic Use
- Acronyms TREND-HD
- 09 Apr 2009 Marketing Authorization Application has been accepted for review by the European Medicines Agency, according to a Amarin Corporation media release.
- 10 Aug 2006 The expected completion date for this trial is now 1 Sep 2007.
- 01 Aug 2006 Status change